138 related articles for article (PubMed ID: 34394748)
1. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
4. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
5. A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.
Liu T; Li Q; Lin Z; Liu C; Pu W; Zeng S; Lai J; Cai X; Zhang L; Wang S; Chen M; Cao W; Gou H; Zhu Q
Cancer Res Treat; 2024 Apr; 56(2):602-615. PubMed ID: 37846469
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
7. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
9. Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers.
Choi JH; Park H; Park JK; Lee JK; Lee KT; Lee KH
Ther Adv Med Oncol; 2024; 16():17588359231225045. PubMed ID: 38249335
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial.
Zhang W; Sun Y; Jiang Z; Qu W; Gong C; Zhou A
Hepatobiliary Surg Nutr; 2023 Feb; 12(1):37-44. PubMed ID: 36860259
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
12. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
[TBL] [Abstract][Full Text] [Related]
13. Biliary tract cancers: systemic therapy for advanced disease.
Martinez FJ; Shroff RT
Chin Clin Oncol; 2020 Feb; 9(1):5. PubMed ID: 32008329
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract][Full Text] [Related]
15. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
Li H; Guo Y; Sun X; Lu Y; Chang S; Wang X; Gao S; Gao C; Zhao T
Front Oncol; 2023; 13():1276037. PubMed ID: 37909023
[TBL] [Abstract][Full Text] [Related]
17. Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Martin RCG; Simo KA; Hansen P; Rocha F; Philips P; McMasters KM; Tatum CM; Kelly LR; Driscoll M; Sharma VR; Crocenzi TS; Scoggins CR
Ann Surg Oncol; 2022 Sep; 29(9):5462-5473. PubMed ID: 35657463
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Franssen S; Holster JJ; Jolissaint JS; Nooijen LE; Cercek A; D'Angelica MI; Homs MYV; Wei AC; Balachandran VP; Drebin JA; Harding JJ; Kemeny NE; Kingham TP; Klümpen HJ; Mostert B; Swijnenburg RJ; Soares KC; Jarnagin WR; Groot Koerkamp B
Ann Surg Oncol; 2024 Jan; 31(1):115-124. PubMed ID: 37814188
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer.
Li X; Zhou N; Yang Y; Lu Z; Gou H
Cancer Sci; 2024 Apr; ():. PubMed ID: 38638055
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
